Skip to main content
. 2016 Feb 5;7(10):11487–11499. doi: 10.18632/oncotarget.7203

Figure 3. LINC00857 is involved in tumor progression.

Figure 3

(A) LINC00857 siRNA knockdown efficiency (48 h) in H1299 and H838 measured by qRT-PCR. (B) Cell proliferation decreased after LINC00857 siRNAs treatment in H1299 and H838 cell lines. (C–D) LINC00857 siRNA knockdown impaired cellular invasion ability in H1299 and H838 cell lines (10X). (E–F) LINC00857 siRNA knockdown impaired cellular migration ability in H1299 and H838 cell lines (10 ×). (G) LINC00857 shRNA knockdown efficiency in H1299 measured by qRT-PCR. (H) Mouse in vivo xenograft tumor growth curves of H1299 cells expressing control and LINC00857 shRNA. (I) Tumor weight of H1299 cells expressing control and LINC00857 shRNA. **p < 0.01, n = 10 mice/group.